Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel, Darolutamide, and Homoharringtonine With ADT in Neoadjuvant Treatment of High-Risk Prostate Cancer
NCT07516704Phase 1Not yet recruiting
- Sponsor
- Zhongda Hospital, Southeast University
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands, Covalent Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of homoharringtonine and darolutamide in prostate cancer (PCa), sponsored by Zhongda Hospital, Southeast University. Primary endpoints: Pathological Complete Response or Minimal Residual Disease Rate, Prostate-Specific Antigen response rate and 1 more. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
homoharringtoninedarolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07516704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07516704.